Compare SPDR Gold Trust (GLD) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? SPDR Gold Trust trades at $380.69 (market cap $141.50B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.91 (market cap $977.37M). The key difference: SPDR Gold Trust is far larger — about 144.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Gold Trust for 75 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GLD | MRVI | |
|---|---|---|
Market Cap | $141.50B | $977.37M |
Volume | 5,707,251 | 2,742,564 |
52-Week High | $495.90 | $9.00 |
52-Week Low | $362.32 | $2.83 |
Typical Hold Time | 75 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD is trading at $380.57, down 0.29% with a bearish technical signal showing 17 sell indicators versus 1 buy. The stock faces pressure from rising Treasury yields and Federal Reserve rate expectations, with support levels at $371-$374 and resistance at $377-$380. Recent news highlights gold's struggle against macroeconomic headwinds despite some safe-haven demand.
The outlook remains cautious with technical indicators signaling bearish momentum and fundamental data unavailable. Key risks include persistent high yields and dollar strength, though some analysts see tactical buying opportunities if prices approach $4,000 support. Wall Street sentiment is mixed amid ongoing rate uncertainty.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
